News

The company reported the completion of enrollment in the first of its two phase III trials earlier this month. Consistent with previous guidance, the company expects to file

The new tests use cell cultures rather than animals to establish the toxicity of cancer drugs and identify contaminated drugs. The approved tests will not only reduce the

The therapeutic agent is huperzine A, a molecule being developed by Neuro-Hitech which is currently undergoing US phase II clinical testing as an orally administered treatment for mild-to-moderate

The aim of the study, in the relapsed subset of treatment experienced hepatitis C (HCV) patients, is to determine the tolerability and antiviral activity of various Actilon containing

The companies will collaborate to identify lead molecules that have defined activities against the antiviral target. Each company will fund its own resources during the course of the

Under the terms of the agreement, NicOx will receive an upfront payment of approximately $11.2 million and is eligible for potential further milestone payments of approximately $340.2 million.

The pivotal program consists of two randomized, double blind, multicenter phase III trials and an open label safety study. The commencement of the program keeps the company on

Specifically, Rigel has been granted six patents in immunology, five patents related to its ubiquitin ligase technology, four patents related to hepatitis-C, six patents in oncology, four patents

The new site to join the phase I/IIa clinical trial of L-Annamycin is the Roswell Park Cancer Institute in Buffalo, New York, a leading US cancer research center.